GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials

Xiaoming Jia, Mahboob Alam, Yumei Ye, Mandeep Bajaj, Yochai Birnbaum

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: The aim of this study is to examine the cardioprotective properties of Glucagon-like peptide-1 receptor agonist, a class of antihyperglycemic therapy, via meta-analysis of four recently published cardiovascular outcomes trials. Methods: Meta-analysis was performed pooling data from the ELIXA, LEADER, SUSTAIN-6 and EXSCEL trials. A random effects model was used to generate risk ratio with 95% confidence interval for cardiovascular and safety outcomes. Results: A total of 33,457 patients were included in the meta-analysis. Based on the study, GLP-1R agonists significantly reduced all-cause mortality (RR 0.89; 95% CI 0.82 to 0.96) and cardiovascular mortality (RR 0.88; 95% CI 0.80 to 0.97) when compared to placebo. When long-acting agents were analyzed alone, reduction in major adverse cardiac events (RR 0.88; 95% CI 0.81 to 0.97) and non-fatal strokes (RR 0.87; 95% CI 0.76 to 0.99) also showed significance. Conclusion: Overall, GLP-1R agonists appear to have cardioprotective properties likely via modification of metabolic parameters such as glycemic control, weight loss, and improvement in blood pressure. Additional studies are warranted to compare cardiovascular outcomes among the different agents.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalCardiovascular Drugs and Therapy
DOIs
StateAccepted/In press - Feb 14 2018

Fingerprint

Meta-Analysis
Cardiovascular Diseases
Mortality
Hypoglycemic Agents
Weight Loss
Stroke
Odds Ratio
Placebos
Confidence Intervals
Blood Pressure
Safety
Glucagon-Like Peptide-1 Receptor
Therapeutics

Keywords

  • Cardiovascular outcomes
  • GLP-1 receptor agonist
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

GLP-1 Receptor Agonists and Cardiovascular Disease : a Meta-Analysis of Recent Cardiac Outcome Trials. / Jia, Xiaoming; Alam, Mahboob; Ye, Yumei; Bajaj, Mandeep; Birnbaum, Yochai.

In: Cardiovascular Drugs and Therapy, 14.02.2018, p. 1-8.

Research output: Contribution to journalArticle

@article{565e2d420fac46e1adc2074d95146c14,
title = "GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials",
abstract = "Purpose: The aim of this study is to examine the cardioprotective properties of Glucagon-like peptide-1 receptor agonist, a class of antihyperglycemic therapy, via meta-analysis of four recently published cardiovascular outcomes trials. Methods: Meta-analysis was performed pooling data from the ELIXA, LEADER, SUSTAIN-6 and EXSCEL trials. A random effects model was used to generate risk ratio with 95{\%} confidence interval for cardiovascular and safety outcomes. Results: A total of 33,457 patients were included in the meta-analysis. Based on the study, GLP-1R agonists significantly reduced all-cause mortality (RR 0.89; 95{\%} CI 0.82 to 0.96) and cardiovascular mortality (RR 0.88; 95{\%} CI 0.80 to 0.97) when compared to placebo. When long-acting agents were analyzed alone, reduction in major adverse cardiac events (RR 0.88; 95{\%} CI 0.81 to 0.97) and non-fatal strokes (RR 0.87; 95{\%} CI 0.76 to 0.99) also showed significance. Conclusion: Overall, GLP-1R agonists appear to have cardioprotective properties likely via modification of metabolic parameters such as glycemic control, weight loss, and improvement in blood pressure. Additional studies are warranted to compare cardiovascular outcomes among the different agents.",
keywords = "Cardiovascular outcomes, GLP-1 receptor agonist, Type 2 diabetes mellitus",
author = "Xiaoming Jia and Mahboob Alam and Yumei Ye and Mandeep Bajaj and Yochai Birnbaum",
year = "2018",
month = "2",
day = "14",
doi = "10.1007/s10557-018-6773-2",
language = "English (US)",
pages = "1--8",
journal = "Cardiovascular Drugs and Therapy",
issn = "0920-3206",
publisher = "Kluwer Academic Publishers",

}

TY - JOUR

T1 - GLP-1 Receptor Agonists and Cardiovascular Disease

T2 - a Meta-Analysis of Recent Cardiac Outcome Trials

AU - Jia, Xiaoming

AU - Alam, Mahboob

AU - Ye, Yumei

AU - Bajaj, Mandeep

AU - Birnbaum, Yochai

PY - 2018/2/14

Y1 - 2018/2/14

N2 - Purpose: The aim of this study is to examine the cardioprotective properties of Glucagon-like peptide-1 receptor agonist, a class of antihyperglycemic therapy, via meta-analysis of four recently published cardiovascular outcomes trials. Methods: Meta-analysis was performed pooling data from the ELIXA, LEADER, SUSTAIN-6 and EXSCEL trials. A random effects model was used to generate risk ratio with 95% confidence interval for cardiovascular and safety outcomes. Results: A total of 33,457 patients were included in the meta-analysis. Based on the study, GLP-1R agonists significantly reduced all-cause mortality (RR 0.89; 95% CI 0.82 to 0.96) and cardiovascular mortality (RR 0.88; 95% CI 0.80 to 0.97) when compared to placebo. When long-acting agents were analyzed alone, reduction in major adverse cardiac events (RR 0.88; 95% CI 0.81 to 0.97) and non-fatal strokes (RR 0.87; 95% CI 0.76 to 0.99) also showed significance. Conclusion: Overall, GLP-1R agonists appear to have cardioprotective properties likely via modification of metabolic parameters such as glycemic control, weight loss, and improvement in blood pressure. Additional studies are warranted to compare cardiovascular outcomes among the different agents.

AB - Purpose: The aim of this study is to examine the cardioprotective properties of Glucagon-like peptide-1 receptor agonist, a class of antihyperglycemic therapy, via meta-analysis of four recently published cardiovascular outcomes trials. Methods: Meta-analysis was performed pooling data from the ELIXA, LEADER, SUSTAIN-6 and EXSCEL trials. A random effects model was used to generate risk ratio with 95% confidence interval for cardiovascular and safety outcomes. Results: A total of 33,457 patients were included in the meta-analysis. Based on the study, GLP-1R agonists significantly reduced all-cause mortality (RR 0.89; 95% CI 0.82 to 0.96) and cardiovascular mortality (RR 0.88; 95% CI 0.80 to 0.97) when compared to placebo. When long-acting agents were analyzed alone, reduction in major adverse cardiac events (RR 0.88; 95% CI 0.81 to 0.97) and non-fatal strokes (RR 0.87; 95% CI 0.76 to 0.99) also showed significance. Conclusion: Overall, GLP-1R agonists appear to have cardioprotective properties likely via modification of metabolic parameters such as glycemic control, weight loss, and improvement in blood pressure. Additional studies are warranted to compare cardiovascular outcomes among the different agents.

KW - Cardiovascular outcomes

KW - GLP-1 receptor agonist

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=85042092281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042092281&partnerID=8YFLogxK

U2 - 10.1007/s10557-018-6773-2

DO - 10.1007/s10557-018-6773-2

M3 - Article

C2 - 29445896

AN - SCOPUS:85042092281

SP - 1

EP - 8

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

ER -